Key Developments: Guided Therapeutics Inc (GTHP.OB)

GTHP.OB on OTC BB

0.22USD
19 Dec 2014
Price Change (% chg)

$-0.00 (-2.22%)
Prev Close
$0.22
Open
$0.22
Day's High
$0.22
Day's Low
$0.22
Volume
188,486
Avg. Vol
219,299
52-wk High
$0.63
52-wk Low
$0.20

Search Stocks

Latest Key Developments (Source: Significant Developments)

Guided Therapeutics announces pricing of $3.8 mln public offering
Wednesday, 26 Nov 2014 10:20am EST 

Guided Therapeutics Inc:Announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of about 16.8 million shares of its common stock, and warrants to purchase shares of its common stock.For gross proceeds to the company of about $3.8 million.Expects to use the cash proceeds to continue to seek FDA approval for LuViva, to repay certain bridge loans, and to support general working capital and operations.  Full Article

Guided Therapeutics, Inc announces secured note offering - Form 8-K
Wednesday, 10 Sep 2014 04:20pm EDT 

Guided Therapeutics, Inc:Enters into note purchase agreement with Tonaquint, Inc., pursuant to which the company sold a secured promissory note to Tonaquint with an initial principal amount of $1,275,000, for a purchase price of $700,000.Note does not bear interest, and will be due six months from issuance.  Full Article

Guided Therapeutics, Inc. initiates Cervical Cancer Screening Trial for LuViva Advanced Cervical Scan
Tuesday, 19 Aug 2014 08:01am EDT 

Guided Therapeutics, Inc:Begins enrollment this week in a multi-center clinical trial to expand claims for the LuViva(reg) Advanced Cervical Scan to include front-line screening for cervical cancer.The trial will be run by principal investigator, Dr. Daron G. Ferris, Director, HPV Prevention Program and Professor of Obstetrics and Gynecology at the Medical College of Georgia at Georgia Regents University in Augusta, Georgia.The blinded trial is expected to enroll between 600 and 800 women, 160 women in Augusta and the remainder in Peru.The results will be used to update and validate LuViva's software for use as a primary screener for cervical disease that leads to cancer, much like the Pap test is used today.LuViva will be compared with Visual Examination with Acetic Acid, or VIA, with cytology, HPV, colposcopy and biopsy, where taken, as the Gold Standard. The trial is expected to take six to nine months.  Full Article

Guided Therapeutics announces completion of private placement of senior convertible notes
Friday, 23 May 2014 04:05pm EDT 

Guided Therapeutics Inc:Announced that it has issued and sold to Magna Group affiliate Hanover Holdings I, LLC the final $2,000,000 in principal amount of senior convertible notes.Intends to use the proceeds for general corporate purposes, including to support manufacturing and marketing of the Guided Therapeutics LuViva Advanced Cervical Scan.  Full Article

Guided Therapeutics Inc announces private placement of senior convertible notes
Thursday, 24 Apr 2014 08:00am EDT 

Guided Therapeutics Inc:Agreed to sell in private placement to Hanover Holdings I, LLC, an affiliate of Magna Group up to $3,000,000 in aggregate principal amount of 6 pct Senior Convertible Notes due 18 months from the date of issuance.Net proceeds are intended to be used for general corporate purposes, including to support manufacturing and marketing of Guided Therapeutics LuViva Advanced Cervical Scan.Etico Capital acted as sole placement agent for private placement.  Full Article

Guided Therapeutics Inc names gene cartwright as Chief Executive Officer
Tuesday, 7 Jan 2014 08:05am EST 

Guided Therapeutics Inc:Says Gene Cartwright has been appointed as the Chief Executive Officer effective Jan. 6.Says Cartwright replaces Mark L. Faupel, who has transitioned to the role of Chief Scientific Officer.  Full Article

Guided Therapeutics Inc Receives $250,000 Payment For Licensing Property
Wednesday, 23 Oct 2013 08:32am EDT 

Guided Therapeutics Inc announced that it received a $250,000 payment from Freedom Meditech, Inc., a San Diego, California based ophthalmic medical device company. The payment was received as part of an agreement under which Guided Therapeutics licensed certain of its non-core intellectual property to Freedom Meditech for technology development related to scanning optical properties of the lens of the eye. Under the agreement, Guided Therapeutics is paid on milestones, minimum royalties and royalties on sales of Freedom Meditech`s products that use Guided Therapeutics` intellectual property, up to a cap of $4 million. To date, payments received by Guided Therapeutics under the license agreement total $300,000.  Full Article

Guided Therapeutics Inc Announces Private Placement of Convertible Preferred Stock and Warrants
Wednesday, 22 May 2013 09:50am EDT 

Guided Therapeutics Inc announced that it has entered into definitive agreements with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock. Gross proceeds to Guided Therapeutics are expected to be approximately $2.6 million, prior to the payment of placement agent fees and expenses. Net proceeds from the private placement are intended to be used to support manufacturing and marketing of the Guided Therapeutics LuViva Advanced Cervical Scan. The private placement remains subject to customary closing conditions and is expected to close on or about May 24, 2013. SunTrust Robinson Humphrey, Inc. acted as sole placement agent for the private placement.  Full Article

Guided Therapeutics Inc Acquires Intellectual Property Rights from Konica Minolta
Wednesday, 6 Feb 2013 08:30am EST 

Guided Therapeutics Inc announced that it has acquired world-wide rights to develop a non-invasive esophageal cancer detection product from Konica Minolta. The product will be based on Guided Therapeutics` patented biophotonic te chnology platform.Under terms of the agreement, Guided Therapeutics acquired both the rights it had licensed to Konica Minolta, and the rights to certain intellectual property invented by Konica Minolta. Upon FDA approval, Konica Minolta would receive a royalty for its licensed intellectual property, if used in the final product. In addition, Guided Therapeutics will now have full worldwide sales and marketing rights, as opposed to a royalty only, as was anticipated under the previous arrangement.  Full Article

No consensus analysis data available.
Search Stocks